A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, multicenter, double-blind, randomized study designed to evaluate the
safety, tolerability, effectiveness, and pharmacokinetics of TLC-3595 activity in
participants with insulin resistance.